Core Viewpoint - The National Healthcare Security Administration (NHSA) has issued a notice outlining nine key tasks for the regulation of the medical insurance fund in 2026, emphasizing the importance of maintaining a high-pressure regulatory environment to ensure the safety of the medical insurance fund [1][2]. Group 1: Regulatory Measures - The notice emphasizes the continuation of special rectification of prominent issues in medical insurance fund management, with local healthcare departments required to ensure accountability at the highest level and implement multiple measures to enhance rectification efforts [1]. - A comprehensive expansion and quality improvement of flying inspections will be promoted, covering all provinces and various stakeholders, including designated medical institutions and insured individuals, across different types of insurance [1]. Group 2: Technological Innovations - The notice highlights the exploration of innovative applications of cutting-edge technologies such as artificial intelligence in regulatory practices, including the development of big data regulatory models to address challenges associated with DRG/DIP payment methods [2]. - The integration of artificial intelligence with imaging recognition is proposed to accurately identify irregularities in implanted medical materials and fraudulent medical practices [2]. Group 3: Systematic Improvements - The notice calls for the continuous improvement of a comprehensive intelligent regulatory system, aiming for over 70% of designated medical institutions to be connected to a pre-reminder system by the end of 2026 [2]. - It also emphasizes the need to establish long-term regulatory mechanisms, including the development of detailed implementation rules for the supervision of medical insurance fund usage and the management of personal accounts in retail pharmacies [2].

Core Viewpoint - The article discusses a bribery case involving a hospital director in Shaanxi Province, highlighting the issue of kickbacks in the medical supply industry and the need for regulatory oversight to ensure fair competition and protect healthcare funds [3][6]. Group 1: Case Details - Li, the director of a bone surgery department, received a total of 2.7205 million yuan in bribes, primarily from orthopedic supply kickbacks [3][4]. - Li accepted 2.469 million yuan from supplier Jia, who promised a 35% kickback on the total supply amount, leading to the use of Jia's products in surgeries from July 2014 to March 2017 [4][5]. - Li also received 231,600 yuan from supplier Sun, who offered a 30% kickback, with the supply agreement in place from January 2018 to January 2019 [5]. Group 2: Implications and Regulatory Actions - The National Healthcare Security Administration (NHSA) stated that medical bribery distorts prescription rights and disrupts normal medical practices, leading to inflated prices for medical supplies [6]. - The NHSA plans to guide local healthcare authorities in evaluating the credit of dishonest companies and enforcing corrective measures to protect healthcare funds [6]. - In 2023, the NHSA has already exposed four bribery cases, indicating a trend of corruption in the pharmaceutical and medical supply sectors [7].